The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders?

EMBO Reports

Volumn 17, Issue 9, 2016, Pages 1245-1249

  Trautmann, Sebastian ^a   Rehm, Jürgen ^a,b   Wittchen, Hans Ulrich ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DISABILITY; DRUG DEPENDENCE; ECONOMIC ASPECT; ECONOMIC DEVELOPMENT; HEALTH CARE COST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; NOTE; ORGANIZATION; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER;

EID: 85027918561     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201642951     Document Type: Note

References (10)

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21: 169–184
2. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 655–679
3. Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, Ferrari AJ, Hyman SE, Laxminarayan R, Levin C et al (2016) Global priorities for addressing the burden of mental, neurological, and substance use disorders. In Mental, neurological, and substance use disorders, Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME (eds), pp 1–27. Washington, DC: The World Bank
4. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382: 1575–1586
5. Hu T (2004) An international review of the economic costs of mental illness. World Bank Working Paper 31
6. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Mowafi M, Pandya A et al (2011) The global economic burden of noncommunicable diseases. Geneva: World Economic Forum
7. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 718–779.
8. Chisholm D, Johansson KA, Reykar N, Megiddo I, Nigam A, Strand KB, Colson A, Fekadu A, Verguet S (2016) Universal health coverage for mental, neurological, and substance use disorders: an extended cost-effectiveness analysis. In Mental, neurological, and substance use disorders, Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME (eds), pp 237–251. Washington, DC: The World Bank
9. Schomerus G, Matschinger H, Angermeyer MC (2006) Alcoholism: illness beliefs and resource allocation preferences of the public. Drug Alcohol Depend 82: 204–210
10. Haro JM, Luis Ayuso-Mateos J, Bitter I, Demotes-Mainard J, Leboyer M, Lewis SW, Linszen D, Maj M, Mcdaid D, Meyer-Lindenberg A et al (2014) ROAMER: roadmap for mental health research in Europe. Int J Methods Psychiatr Res 23: 1–14